Genetics of Alzheimer’s disease — routes to the pathophysiology

  • Lars Lannfelt
  • C. Nordstedt
Conference paper


Considerable advances have been made the last years in the understanding of the pathogenesis of Alzheimer’s disease (AD): Several pathogenic mutations have been found in the amyloid precursor protein gene on chromosome 21. Two other dominantly operating genes on chromosome 14 and 1 were recently cloned, named presenilin 1 and 2, respectively. Mutations in these genes give rise to AD with a very early age of onset. Increased Aβ1-42 is most likely the pathogenic mechanism in all these cases. A susceptibility gene for AD has also been found. There is an association between the ɛ4 allele of the apolipoprotein E (APOE) gene and late-onset AD. The ɛ4 allele increases the risk for AD, although some ɛ4 homozygotes may live a long life without developing AD. The mechanism by which APOE ɛ4 promotes development of AD is most likely increased plaque formation. The new knowledge on pathogenic mechanisms of the disease gives opportunities for alternative strategies for therapeutic intervention.


Amyloid Precursor Protein Amyloid Precursor Protein Processing Amyloid Precursor Protein Gene Amyloid Precursor Protein Mutation Presenilin Mutation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Axelman K, Basun H, Winblad B, Lannfelt L (1994) A large Swedish family with Alzheimer’s disease with a codon 670/671 amyloid precursor protein mutation: A clinical and genealogical investigation. Arch Neurol 51: 1193 – 1197PubMedGoogle Scholar
  2. Cai XD, Golde TE, Younkin SG (1993) Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science 259: 514 – 516PubMedCrossRefGoogle Scholar
  3. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P et al (1992) Mutation of the p-amyloid precursor protein in familial Alzheimer’s disease increases β-protein production. Nature 360: 672 – 674PubMedCrossRefGoogle Scholar
  4. Citron M, Vigo-Pelfrey C, Teplow DB, Miller C, Schenk D, Johnston J, Winblad B, Venizelos N, Lannfelt L, Selkoe DJ (1994) Excessive production of amyloid (3- protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer’s disease mutation. Proc Natl Acad Sci USA 91: 11993 – 11997PubMedCrossRefGoogle Scholar
  5. Citron M, Diehl TS, Gordon G, Biere AL, PS, Selkoe DJ (1996) Evidence that the 42- and 40-amino acid forms of amyloid (3 protein are generated from the β-amyloid precursor protein by different protease activities. Proc Natl Acad Sci USA 93: 13170 – 13175PubMedCrossRefGoogle Scholar
  6. Cruts M, Hendriks L, Van Broeckhoven C (1996) The presenilin genes: a new gene family involved in Alzheimer disease pathology. Hum Mol Genet 5: 1449 – 1455PubMedGoogle Scholar
  7. Cummings BJ, Cotman CW (1995) Image analysis of β-amyloid load in Alzheimer’s disease and relation to dementia. Lancet 346: 1524 – 1527PubMedCrossRefGoogle Scholar
  8. Gandy S, Caporaso G, Buxbaum J, Frangione B, Greengard P (1994) APP processing, Aβ amyloidogenesis, and the pathogenesis of Alzheimer’s disease. Neurobiol Aging 15: 253 – 256PubMedCrossRefGoogle Scholar
  9. Glenner GG, Wong CW (1984) Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122: 1131 – 1135PubMedCrossRefGoogle Scholar
  10. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L et al (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349: 704 – 706PubMedCrossRefGoogle Scholar
  11. Jarret JT, Lansbury PT (1993) Seeding “one-dimensional crystallization” of amyloid. A pathogenic mechanism in Alzheimer’s disease and scrapie? Cell 73: 1055 – 1058CrossRefGoogle Scholar
  12. Johnston J, Cowburn RF, Norgren S, Wiehager B, Venizelos N, Winblad B, Vigo-Pelfrey C, Schenk D, Lannfelt L, O’Neill C (1994) Increased (3-amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer’s disease APP670/671 mutation. FEBS Lett 354: 274 – 278PubMedCrossRefGoogle Scholar
  13. Kang J, Lemaire H-G, Unterbeck A, Salbaum JM, Masters CL, Grzeschik K-H et al (1987) The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell- surface receptor. Nature 325: 733 – 736PubMedCrossRefGoogle Scholar
  14. Lannfelt L, Bogdanovic N, Appelgren H, Axelman K, Lilius L, Hansson G, Schenk D, Hardy J, Winblad B (1994) Amyloid precursor protein mutation causes Alzheimer’s disease in a Swedish family. Neurosci Lett 168: 254 – 256PubMedCrossRefGoogle Scholar
  15. Levy-Lahad E, Wasco W, Poorkaj P, Romano D, Oshima J, Pettingell WH et al (1995) Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 269: 973 – 977PubMedCrossRefGoogle Scholar
  16. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L (1992) A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N- terminus of (3-amyloid. Nat Genet 1: 345 – 347PubMedCrossRefGoogle Scholar
  17. Nöslund J, Thyberg J, Tjernberg LO, Wernstedt C, Karlstrom AR, Bogdanovic N, Gandy SE, Lannfelt L, Terenius L, Nordstedt C (1995) Aβ and apolipoprotein E complexes from Alzheimer disease brain: purification and structural characterization. Neuron 15: 219 – 228Google Scholar
  18. Olson M, Shaw C (1969) Presenil dementia and Alzheimer’s disease in mongolism. Brain 92: 147 – 156PubMedCrossRefGoogle Scholar
  19. Perez-Tur J, Froelich S, Prihar G, Crook R, Baker M, Duff K, Wragg M, Busfield F, Clark RF, Roques P, Fuldner RA, Johnston J, Forsell C, Axelman K, Lilius L, Cowburn R, Houlden H, Karran E, Roberts GW, Rossor M, Adams MD, Hardy J, Goate A, Lannfelt L, Hutton M (1995) A mutation in Alzheimer’s disease destroying a splice acceptor site in the presenilin-1 gene. Neuroreport 7: 297 - 301PubMedGoogle Scholar
  20. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y et al (1995) Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature 376: 775 – 778PubMedCrossRefGoogle Scholar
  21. Schellenberg GD, Bird TD, Wijsman EM, Orr HT, Anderson L, Nemens E et al (1992) Genetic linkage evidence for a familial Alzheimer’s disease locus on chromosome 14. Science 258: 668 – 671PubMedCrossRefGoogle Scholar
  22. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larsson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S (1996) Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 2: 864 – 869PubMedCrossRefGoogle Scholar
  23. Selkoe DJ (1993) Physiological production of the (3-amyloid protein and the mechanism of Alzheimer’s disease. Trends Neurol Sci 16: 403 – 409CrossRefGoogle Scholar
  24. Selkoe DJ (1997) Alzheimer’s disease: genotypes, phenotype, and treatments. Science 275: 630 – 631PubMedCrossRefGoogle Scholar
  25. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M et al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 375: 754 – 760PubMedCrossRefGoogle Scholar
  26. Sjgren T, Sjögren H, Lindgren AG (1952) Morbus Alzheimer and Morbus Pick. A genetic, clinical and patho-anatomical study. Acta Psychiatr Scand Suppl 82Google Scholar
  27. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: High avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer’s disease. Proc Natl Acad Sci USA 90: 1977 – 1981PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2000

Authors and Affiliations

  • Lars Lannfelt
    • 1
  • C. Nordstedt
    • 2
  1. 1.Karolinska Institute, Department of Neurotec, Novum KFCHuddinge University HospitalHuddingeSweden
  2. 2.Hoffman La Roche Ltd, Pharmaceutical DivisionPreclinical CNS Research DepartmentBaselSwitzerland

Personalised recommendations